We are a CNS-focused company providing drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models. Our capabilities include dose-response studies, pharmacodynamics, model phenotyping and phenotypic screening for lead selection and validation in Epilepsy, Movement disorders and cognitive disorders.
Hugo Monchal
Our Representatives
Since 2005, SynapCell has built its reputation as a leader in predictive efficacy testing in the field of CNS disorders, supporting international biopharmaceutical companies in identifying their most promising drug candidates and securing their preclinical to clinical roadmap.
Driven by a constantly growing innovation pipeline, we have been developing, consolidating, and expanding the applications of Cue®, our proprietary technology platform towards therapeutic areas with high unmet needs.
The translational, robust, and objective EEG biomarkers we have discovered in clinically relevant animal models in vivo have enabled our clients to unlock the true pharmacodynamic potential of their drug candidates that target epileptic, motor (Essential Tremors, Parkinson’s disease, LID), or cognitive disorders for example.
Our clients’ base feature small ventures to large pharmaceutical companies, who value the extra mile we are delivering across our expertise, ability to adapt to their timelines and scientific constraints and excellent quality of work form study design to final report.
Daily interactions with our experts allow for making the most out of a project at every step and our commitment for delivering clear, comprehensive, and documented information help our clients status on a GO/NO GO decision for the next step of your drug development.